Ablynx appoints Edwin Moses as CEO

29-Mar-2006

Ablynx has announced that Dr Edwin Moses has accepted the Board's offer to extend his role as Chairman to include that of Chief Executive Officer. Edwin has been non-Executive Chairman of Ablynx since November 2004. He takes over the CEO role from Mark Vaeck, Ph.D., who will continue to support the Company in a consultative capacity.

Edwin is a business leader with a successful track record in creating company value and attracting finance, both in the private and public arena. He is internationally experienced in the life science industry, having spent extended periods in Germany, UK and Italy as well as having had extensive business activities in the USA. Over the past five years he has made a substantial contribution at Board level (primarily as Chairman) to over 15 European life sciences companies. Prior to this, as CEO and then Chairman of Oxford Asymmetry International (OAI), he successfully grew the Company between 1993 and 1998 from four people to 250 people, through several venture capital financing rounds then to a full listing on the London Stock Exchange in 1998. He then led the cross border sale of OAI to Evotec Biosystems AG two years later.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances